Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft
The Use of Topical Tranexamic Acid Versus Thrombin Spray for the Management of Split Thickness Skin Graft Recipient Site in Burn Management
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * English or Spanish speaking * Flame or scald burn injury * \<=10% total body surface area (TBSA) partial thickness * \<= 5% total body surface area (TBSA) deep partial or full thickness * Skin graft harvested at 1/12 inch depth, meshed 1:1 or pie crusted if the area is a small functional area Exclusion Criteria: * \>10% total body surface area (TBSA) partial thickness burn * \>5% total body surface area (TBSA )surgical area of burn injury (deep partial or full thickness injury) * Traumatic or chemical burn mechanism * Patients on immunosuppression * Uncontrolled diabetes * Known diagnosis of peripheral vascular disease or diagnosis at time of injury * Pregnant women * Patients with acquired defective color vision * Patients with subarachnoid hemorrhage * Patients with active intravascular clotting or known hypersensitivity reactions to tranexamic acid * Inability to give informed consent
About the study
Investigators hypothesize that topical tranexamic acid will have better or comparable efficacy to topical thrombin in reducing hematoma formation at the wound base. The purpose of the study is to demonstrate that topical tranexamic acid will be a non-inferior alternative medication to the current standard of care,THROMBIN-JMI® , and at a lower cost to the health system.
What is being tested
- Tranexamic acid (drug)
- Thrombin JMI (drug)
- skin graft (procedure)
Sponsor: University of Kansas Medical Center · Participants: 62 · Started: Jul 11, 2024
Contact the study team
- Jessica Reynolds, BSN · Phone: 913-588-5000
Official record on ClinicalTrials.gov — NCT06379724
Locations in the U.S.
| Kansas | The University of Kansas Health System, Kansas City |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.